Download Download this free, 150-page Pharmaceutical Serialization Playbook jam-packed with strategies for success and pitfalls to avoid.  Learn more >>
Article |

Healthy developments stirring in pharmaceutical contract manufacturing

Cel-Sci, Genzyme, and Pfizer announce contract manufacturing, outsourcing plans for drug and biopharmaceutical products.
FILED IN:  Package Feature  > Shelf life  > Aseptic

Recent reports from in-Pharma illustrate that production within the life science industry is off to an impressive start in this new year.

For example, the Web site reports that Cel-Sci has validated production equipment at its Baltimore, MD, GMP facility for aseptic filling and is ready to commence manufacture of its cancer drug Multikine. Once Cel-Sci has produced enough material for a Phase III trial of the drug, it says it will offer contract manufacturing services from the facility.

Earlier, in-Pharma noted that Genzyme was “outsourcing the fill and finish manufacturing of several major drugs to Hospira in response to in-house difficulties at its Allston Landing facility in Boston.”

Meanwhile, “Pfizer will soon sell more generic pharmaceuticals in the U.S. after its agreement with Indian non-branded drugmaker Strides Arcolab,” according to in-Pharma

These developments provide a beacon of hope for 2010.

Related Sponsored Content

E-Book Special Report
Total Cost of Ownership
Sign up to receive timely updates from our editors and download this E-Book Special Report to learn how to calculate the true Total Cost of Ownership (TCO) of your packaging machinery.


Don't miss intelligence crucial to your job and business!
Click on any newsletter to view a sample. Enter your email address below to sign up!
Each newsletter ranges in frequency from once per month to a few times per month at most.